Back to Authors

Guangqi, E

Mayo Clinic

Mayo Clinic

Citations 2

VEGF Exerts an Angiogenesis-Independent Function in Cancer Cells to Promote Their Malignant Progression
Cao, Ying , Guangqi, E, Wang, Enfeng , Pal, Krishnendu , Dutta, Shamit K., Bar‐Sagi, Dafna , Mukhopadhyay, Debabrata , Pal, Krishnendu

Cancer Research | June 13, 2012 | Volume: 72 | Issue: 16 | Pages: 3912-3918

10.1158/0008-5472.can-11-4058 Get It

Abstract VEGF/vascular permeability factor (VEGF/VPF or VEGF-A) is a pivotal driver of cancer angiogenesis that is a central therapeutic target in the treatment of malignancy. However, little work has been devoted to investigating functions of VEGF that are independent of its proangiogenic activity. Here, we report that VEGF produced by tumor cells acts in an autocrine manner to promote cell growth through interaction with the VEGF receptor neuropilin-1 (NRP-1). Reducing VEGF expression by tumor cells induced a differentiated phenotype in vitro and inhibited tumor forming capacity in vivo, independent of effects on angiogenesis. Autocrine activation of tumor cell growth was dependent on signaling through NRP-1, and Ras was determined to be a critical effector signaling molecule downstream of NRP-1. Our findings define a novel function for VEGF in dedifferentiation of tumor cells expanding its role in cancer beyond its known proangiogenic function. Cancer Res; 72(16); 3912–8. ©2012 AACR.
NHERF-2 maintains endothelial homeostasis
Wang, Enfeng , Dutta, Shamit K., Vohra, Pawan K., Guangqi, E, Prakash, Y. S. , Bhattacharya, Resham , Mukhopadhyay, Debabrata , Prakash, Y S

Blood | February 18, 2012 | Volume: 119 | Issue: 20 | Pages: 4798-4806

10.1182/blood-2011-11-392563 Get It

AbstractThe Na+/H+ exchanger regulatory factor-2 (NHERF-2) is an integral component of almost all endothelial cells (ECs), yet its endothelial function is not known. Here, we found that NHERF-2, is a key regulator of endothelial homeostasis because NHERF-2–silenced ECs proliferate at a much higher rate even in the absence of mitogens such as VEGF compared with control ECs. We further show that the hyperproliferation phenotype of NHERF-2–silenced EC is because of an accelerated cell cycle that is probably caused by a combination of the following factors: increased cytoplasmic calcium, increased expression of c-Myc, increased expression of cyclin D1, and reduced expression of p27. Using an experimental mouse model of human hemangioma, we found that the endothelial neoplasms derived from NHERF-2–silenced cells were much larger in volume than those derived from control cells. Thus, NHERF-2 is a negative regulator of endothelial proliferation and may have important roles in endothelial homeostasis and vascular modeling.